Peficitinib (brand name Smyraf) is a pharmaceutical drug used for the treatment of rheumatoid arthritis.

It belongs to the class of drugs known as Janus kinase inhibitors (JAK inhibitors).

[1][2] Peficitinib was approved for use in Japan in 2019.

This antineoplastic or immunomodulatory drug article is a stub.

You can help Wikipedia by expanding it.